Liquidia Corporation
LQDA
NASDAQ·Healthcare·Medical - Pharmaceuticals·Mkt cap $6.0B
$67.76
▲ +1.27%
P/E
43.74
Mkt Cap
$6.0B
52-Wk Range
$21.15–$93.61
52-Week Range
$21.15 - $93.61
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 134.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary LiquidiaFill technology for advanced drug delivery
- First-mover advantage with YUTREPIA inhaled formulation in PAH market
- Established distribution network for generic treprostinil generating cash flow
- Specialized expertise in pulmonary and cardiovascular disease treatments
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Strong growth ahead
YUTREPIA commercialization and market penetration in PAH patient population
Value
Valued in line with Biotech & Therapeutics peers (1.0x).
Momentum
Hot
+21.4% over 3m
Quality
Excellent
High-growth business (500% revenue growth, 92% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying LQDA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 12, 2026
Reported EPS of $0.74 vs $0.76 consensus (-2.4% surprise). Revenue of $171.7M vs $168.5M expected (+1.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-2.4%
Revenue trend · last 8Q
—
-36%
+5%
+142%
+1122%
+3055%
+4158%
+1843%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$4.4M
$2.9M
$3.1M
$8.8M
$54.3M
$92.0M
$132.9M
$171.7M
Margins · last 8Q
Gross
93.3%
Operating
49.8%
Profit
43.5%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Wells Fargo · Aug 13, 2026
vs Industry
How LQDA stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related